This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.
Right arrow Articles by Wilson, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.
Right arrow Articles by Wilson, J. M.

 Previous Article  |  Next Article 

Journal of Virology, November 2007, p. 11840-11849, Vol. 81, No. 21
0022-538X/07/$08.00+0     doi:10.1128/JVI.01253-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+ T-Cell Responses in Mice{triangledown}

Jianping Lin, Yan Zhi, Lauren Mays, and James M. Wilson*

Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 125 S. 31st Street, Philadelphia, Pennsylvania 19104

Received 8 June 2007/ Accepted 10 August 2007

We recently discovered an expanded family of adeno-associated viruses (AAVs) that show promise as improved gene therapy vectors. In this study we evaluated the potential of vectors based on several of these novel AAVs as vaccine carriers for human immunodeficiency virus type 1 Gag. Studies with mice indicated that vectors based on AAV type 7 (AAV7), AAV8, and AAV9 demonstrate improved immunogenicity in terms of Gag CD8+ T-cell and Gag antibody responses. The quality of these antigen-specific responses was evaluated in detail for AAV2/8 vectors and compared to results with an adenovirus vector expressing Gag (AdC7). AAV2/8 produced a vibrant CD8+ T-cell effector response characterized by coexpression of gamma interferon and tumor necrosis factor alpha as well as in vivo cytolytic activity. No CD8+ T-cell response generated by any of the AAVs was effectively boosted with AdC7, a result consistent with the finding of a relative lack of cells expressing interleukin-2 (IL-2) or a central memory phenotype at 3 months after the prime. The primary response to an AdC7 vaccine differed from that generated by AAVs in that the peak effector response evolved into populations of Gag-specific T cells expressing high levels of cytokines, including IL-2, and with effector memory and central memory phenotypes. A number of mechanisms could be considered to explain the aberrant activation of CD8+ T cells by AAV, including insufficient inflammatory responses, CD4 help, and/or chronic antigen expression and T-cell exhaustion. Interestingly, the B-cell response to AAV-encoded Gag was quite vibrant and easily boosted with AdC7.


* Corresponding author. Mailing address: 125 S. 31st Street, TRL, Suite 2000, Philadelphia, PA 19104-3403. Phone: (215) 898-0819. Fax: (215) 898-6588. E-mail: wilsonjm{at}mail.med.upenn.edu

{triangledown} Published ahead of print on 22 August 2007.


Journal of Virology, November 2007, p. 11840-11849, Vol. 81, No. 21
0022-538X/07/$08.00+0     doi:10.1128/JVI.01253-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., Wilson, J. M. (2009). Adeno-Associated Virus Capsid Structure Drives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins. J. Immunol. 182: 6051-6060 [Abstract] [Full Text]  
  • Velazquez, V. M., Bowen, D. G., Walker, C. M. (2009). Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood 113: 538-545 [Abstract] [Full Text]